Literature DB >> 7424940

Parapneumonic effusions.

R W Light, W M Girard, S G Jenkinson, R B George.   

Abstract

In this study the incidence and course of pleural effusions (parapneumonic effusions) in patients with acute bacterial pneumonia were prospectively evaluated. Bilateral decubitus chest x-ray films were obtained within 72 hours of admission in 203 patients with an acute febrile illness, purulent sputum and an infiltrate evident on the chest film. Ninety of the 203 patients (44 percent) had pleural effusions. Parapneumonic effusions, which required chest tubes for resolution and/or on which the pleural fluid cultures were positive, were classified as complicated parapneumonic effusions. The 10 patients with complicated parapneumonic effusions had clinical characteristics similar to the remainder of the group and could be separated from the 80 with uncomplicated effusions only by pleural fluid analysis. A pleural fluid pH below 7.00 and/or a glucose level below 40 mg/100 ml are indications for immediate tube thoracostomy. In patients with pleural fluid pH between 7.00 and 7.20 or lactic dehydrogenase (LDH) above 1,000 IU/1,000 ml, tube thoracostomy should be considered, but each case should be individualized; serial studies of the pleural fluid are useful in some of these cases. Patients with pleural fluid pH above 7.20 and pleural fluid LDH below 1,000 mg/100 ml rarely have complicated parapneumonic effusions and do not require serial therapeutic thoracenteses.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7424940     DOI: 10.1016/0002-9343(80)90460-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  57 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

Review 2.  Clinical use of cefuroxime in paediatric community-acquired pneumonia.

Authors:  C Olivier
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

3.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 4.  Post-resection complications: abscesses, empyemas, bronchopleural fistulas.

Authors:  Matthew Egyud; Kei Suzuki
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

5.  The role of pleural fluid-serum gradient of tumor necrosis factor-alpha concentration in discrimination between complicated and uncomplicated parapneumonic effusion.

Authors:  M Odeh; B Makhoul; E Sabo; I Srugo; A Oliven
Journal:  Lung       Date:  2005 Jan-Feb       Impact factor: 2.584

6.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society.

Authors:  L A Mandell; T J Marrie; R F Grossman; A W Chow; R H Hyland
Journal:  Can J Infect Dis       Date:  2000-09

7.  Further comments on pleural effusions.

Authors:  G M Tisi
Journal:  West J Med       Date:  1982-08

8.  Intrapleural streptokinase treatment in children with empyema.

Authors:  Metin Aydoğan; Ayşen Aydoğan; Ayla Ozcan; Melih Tugay; Ayse Sevim Gokalp; Emin Sami Arisoy
Journal:  Eur J Pediatr       Date:  2007-08-21       Impact factor: 3.183

9.  Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions.

Authors:  Eva Ruiz; Carmen Alemán; José Alegre; Jasone Monasterio; Rosa Ma Segura; Lluis Armadans; Ana Vázquez; Teresa Soriano; Tomás Fernández de Sevilla
Journal:  Lung       Date:  2005 May-Jun       Impact factor: 2.584

10.  Rapid detection of pneumococcal antigen in pleural fluid of patients with community acquired pneumonia.

Authors:  W G Boersma; A Löwenberg; Y Holloway; H Kuttschrütter; J A Snijder; G H Koëter
Journal:  Thorax       Date:  1993-02       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.